Opexa Therapeutics

Opexa Therapeutics , formerly known as PharmaFrontiers, is a U.S. biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies.
History
Founded in 2003, the company was originally known as PharmaFrontiers Corp. In October 2004 PharmaFrontiers acquired the privately held company Opexa Pharmaceuticals Inc. In June 2006 the company changed its name to Opexa Therapeutics, Inc.
In 2009 the company sold its stem cell technology to Novartis and focused all of its attention on the continuing development of Tovaxin.
Research areas and products
Key products and research include:
*Tcelna, previously known as Tovaxin: A proposed T cell therapeutic vaccine for multiple sclerosis, which was granted Fast Track status by the U.S. Food and Drug Administration. In January 2011 the FDA approved the product for Phase 3 clinical trials.
*Heart: early development-stage stem cell therapy (currently in standby)
*Diabetes: early development-stage stem cell therapy (currently in standby)
Location
Opexa Therapeutics is located in The Woodlands, Texas north of Houston, Texas. The company has a facility on in The Woodlands.
References
<references />

Main Menu

See Also

Main Menu